Keros Suspends Two Arms of Hypertension Study After Reports of Pericardial Effusion
Kerros stock plummeted more than 70% premarket Thursday and Truist Securities analysts predict it will remain under pressure until the safety concerns for cibotercept are resolved.
Keros Suspends Two Arms of Hypertension Study After Reports of Pericardial Effusion Read More »
